I'm going to hold until some big pharma buys them after the June presentation:
. A final presentation will report data from a study of tesetaxel plus capecitabine (Xeloda®; Hoffmann La Roche, Inc.), a drug combination that will be featured in Genta's late-stage clinical trials.